Royalty Report: Drugs, Cancer, Pharmaceuticals – Collection: 28952

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Cancer
  • Pharmaceuticals
  • Disease
  • Delivery
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 28952

License Grant
Licensor grants to the Licensee a worldwide, exclusive license under the Licensed Proprietary Property to make, use or sell Products for the Field of Use. Licensor shall not license any other party rights to deliver camptothecin or analogues thereof, alone or in combination with another drug, in liposomes, lipid complexes or other liposome particles, to the respiratory tract via aerosol droplets. Licensor grants the right to grant sub-licenses to others within the scope of and under the terms and conditions of the License.
License Property
Licensor is the owner of certain inventions, discoveries, and know-how comprising certain Proprietary Property related to Camptothecin delivery.

Camptothecin is a cytotoxic quinoline alkaloid discovered in the screening of natural products for anticancer drugs. It was isolated from the bark and stem of Camptotheca acuminata (Camptotheca, Happy tree), a tree native to China used as a cancer treatment in Traditional Chinese Medicine, showing anticancer activity in preliminary clinical trials but also low solubility and (high) adverse drug reaction. CPT analogues have been approved and are used in cancer chemotherapy.

The license is for the rights to deliver paclitaxel or analogues thereof, alone or in combination with another drug, in liposomes, lipid complexes or other liposome particles, to the respiratory tract via aerosol droplets.

The methods, composition, and information claimed in U.S. Patent No. 5,049,388, entitled Small Particle Aerosol Liposome and Liposome-Drug Combinations for Medical Use and U.S. Patent Application Serial No. 08/933,254, entitled Small Particle Liposome Aerosols for Delivery of Anti-Cancer Drugs.

Field of Use
These are used for Cancer therapy in humans wherein paclitaxel or analogues thereof are delivered in liposomes, lipid complexes, or other liposome particles, to the respiratory tract via aerosol droplets.

IPSCIO Record ID: 260458

License Grant
University grants to Licensee the right and exclusive license in the Territory to make, have made, use, import, and sell the Licensed Technology in the Field and to practice under the Patent Rights in the Field to the end of the term for which the Patent Rights are granted, unless this Agreement is terminated sooner as provided herein.
License Property
The Licensed Technology is certain Patent Rights, entitled Camptothecin Analogs and Methods of Preparation Thereof.

Camptothecin is a topoisomerase inhibitor.  It was isolated from the bark and stem of Camptotheca acuminata (Camptotheca, Happy tree), a tree native to China used as a cancer treatment in Traditional Chinese Medicine.  Camptothecin showed remarkable anticancer activity in preliminary clinical trials.

Field of Use
The Field shall mean all therapeutic uses in humans and animals.  Licensee is focused on acquiring, developing and eventually commercializing innovative products for the treatment of cancer.

IPSCIO Record ID: 27197

License Grant
We signed a license agreement to develop and commercialize liposome encapsulated paclitaxel (LEP).
License Property
LEP allows cancer patients to tolerate higher dosages of chemotherapy, providing greater therapeutic value in a number of types of cancer tumors; liposome compounds worldwide; liposome products consist of spheres of sub cellular size composed primarily of phospholipids, certain of which are the primary components of living cell membranes, and can be made to contain and deliver drugs.  This membrane encapsulation feature of liposomes enables the entrapped drug to be circulated in the bloodstream in higher concentrations for longer periods of time than the free drug.  We initiated a Phase I clinical study on LEP in September of 1998 for patients with lung cancer.
Field of Use
The rights granted apply to cancer.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.